These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 21041383)

  • 1. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
    Srivastava RK; Kurzrock R; Shankar S
    Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis.
    Shankar S; Ganapathy S; Chen Q; Srivastava RK
    Mol Cancer; 2008 Jan; 7():16. PubMed ID: 18226269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
    Shankar S; Ganapathy S; Srivastava RK
    Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
    Nidhyanandan S; Boreddy TS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Narayanan S
    Eur J Pharmacol; 2015 Oct; 764():508-519. PubMed ID: 26209365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
    Shankar S; Chen Q; Ganapathy S; Singh KP; Srivastava RK
    Mol Cancer Ther; 2008 Aug; 7(8):2328-38. PubMed ID: 18723480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
    Bagci-Onder T; Agarwal A; Flusberg D; Wanningen S; Sorger P; Shah K
    Oncogene; 2013 Jun; 32(23):2818-27. PubMed ID: 22824792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
    Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
    Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Tellurium-bridged β-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.
    Lin T; Ding Z; Li N; Xu J; Luo G; Liu J; Shen J
    Carcinogenesis; 2011 Feb; 32(2):154-67. PubMed ID: 21081474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
    Venza I; Visalli M; Oteri R; Teti D; Venza M
    Int Immunopharmacol; 2014 Aug; 21(2):439-46. PubMed ID: 24946096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
    Shah P; Gau Y; Sabnis G
    Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5.
    Chen Y; Wei L; Zhang X; Liu X; Chen Y; Zhang S; Zhou L; Li Q; Pan Q; Zhao S; Liu H
    Oncol Rep; 2018 Nov; 40(5):2435-2444. PubMed ID: 30132536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulinastatin exerts synergistic effects with taxotere and inhibits invasion and metastasis of breast cancer by blocking angiogenesis and the epithelial-mesenchymal transition.
    Gao F; Sun Z; Sun X; Zhang Y; Wang H; Zhong B; Luo J; Zhao X
    Cancer Biother Radiopharm; 2013 Apr; 28(3):218-25. PubMed ID: 23477357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
    Siddiqui IA; Malik A; Adhami VM; Asim M; Hafeez BB; Sarfaraz S; Mukhtar H
    Oncogene; 2008 Mar; 27(14):2055-63. PubMed ID: 17998943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.
    Nesterenko I; Wanningen S; Bagci-Onder T; Anderegg M; Shah K
    PLoS One; 2012; 7(11):e49219. PubMed ID: 23145127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial to mesenchymal transition is associated with rapamycin resistance.
    Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.